2-[(1S)-1-[(2-amino-7H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)quinazolin-4-one | 1431697-74-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-[(1S)-1-[(2-amino-7H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)quinazolin-4-one
• CAS: 1431697-74-3
• 化学式: C₂₃H₂₂N₈O
• 分子量: 426.5
• InChiKey: PUYVJBBSBPUKBT-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  125
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Combination therapies
  申请人：Infinity Pharmaceuticals, Inc.

  公开号：US11110096B2

  公开（公告）日：2021-09-07

  Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor or a pharmaceutically acceptable form thereof, and a Bcl-2 inhibitor or a pharmaceutically acceptable form thereof. Also provided herein are methods for treating cancer comprising administration the compositions, and uses of the compositions, e.g., for the treatment of cancer.

  本文提供的药物组合物包含磷脂酰肌醇3-激酶抑制剂或其药学上可接受的形式，以及Bcl-2抑制剂或其药学上可接受的形式。本文还提供了治疗癌症的方法，包括给药该组合物，以及该组合物的用途，例如用于治疗癌症。
• COMBINATION THERAPIES
  申请人：INFINITY PHARMACEUTICALS, INC.

  公开号：US20150320755A1

  公开（公告）日：2015-11-12

  Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor or a pharmaceutically acceptable form thereof, and a Bcl-2 inhibitor or a pharmaceutically acceptable form thereof. Also provided herein are methods for treating cancer comprising administration the compositions, and uses of the compositions, e.g., for the treatment of cancer.
• Methods and Pharmaceutical Compositions for Treating Lymphoid Malignancy
  申请人：The Trustees of Columbia University in the City of New York

  公开号：US20170246173A1

  公开（公告）日：2017-08-31

  The present invention provides, inter alia, methods for treating, preventing, or ameliorating the effects of a lymphoid malignancy, such as those associated with a mutated phosphatase and tensin homolog (PTEN) gene, or T-cell acute lymphoblastic leukemia (T-ALL). These methods include administering to a subject an effective amount of a phosphoinositide 3-kinase-delta (PI3Kδ) inhibitor and a phosphoinositide 3-kinase-gamma (PI3Kγ) inhibitor. The present invention also provides pharmaceutical compositions for treating the effects of a lymphoid malignancy. This invention further provides a method for identifying a subject who may benefit from co-treatment with a PI3Kδ inhibitor and a PI3Kγ inhibitor. This method includes determining from a sample of the subject whether the subject has a mutated PTEN gene. Additionally, this invention provides methods for identifying a compound that has both PI3Kδ and PI3Kγ inhibitory activity.
• Compounds, Compositions, and Methods for Treating T-Cell Acute Lymphoblastic Leukemia
  申请人：The Trustees of Columbia University in the City of New York

  公开号：US20200165211A1

  公开（公告）日：2020-05-28

  In an aspect, the disclosure provides for compounds (II), compositions, and methods of administering the compounds and compositions to a patient in need thereof. In another aspect, the disclosure relates to compounds and compositions for treating cancer, for example, lymphoid leukemia. The disclosure further provides for compounds which inhibit two phosphoinositide 3-kinase (PI3K) isoforms, y and δ, pharmaceutical compositions comprising said compounds, and methods of using said compounds and pharmaceutical compositions for treatment, amelioration, and/or prevention of non-Hodgkin lymphoma.
• METHODS OF MAKING CELLULAR THERAPIES
  申请人：Secura Bio, Inc.

  公开号：US20220387491A1

  公开（公告）日：2022-12-08

  The present disclosure relates generally to methods of making immune effector cells, such as those engineered to express a Chimeric Antigen Receptor (CAR) including CAR-T cells, and compositions comprising the same, for use in treating cancer.